can please tell me where did O3039 come from?
and what is the r1 value for it?
Dear Dr Khaled
O-3039 is a vaccine supplied by Boehringer Ingelheim - I suggest that you contact the company for further information about this vaccine strain.
In terms of vaccine matching data (r1-values) - you can find these values in the quarterly reports of WRLFMD/EuFMD (see: https://www.wrlfmd.org/ref-lab-reports)
All the best
In the discussion forum, I briefly introduced our ideas to develop a dynamic "FMD Dashboard" to allow users to browse, analyse and retrieve FMD datasets. We are still at the planning stages for these tools and welcome any feedback. The survey (in the link below) has been put together to try to capture and prioritise the requirements for this system - if you are interested, please feel free to complete this survey - or pass on to others that might want to influence how we develop this capacity:
RE: the importance of booster vaccination doses for FMD
I didn't have much time in the talk to cover FMD vaccines - but the question raised here is very important. I am not sure that I can directly answer the question - but there are certainly many anecdotal reports of FMD vaccines being used in the field with only a single dose of the vaccine. There are a number of published studies that clearly demonstrate the benefits of booster (two shots) to provide broader, higher FMDV-specific immunity with a longer duration - and (as far as I'm aware) most of the vaccination regimes provided by the commercial suppliers require that two doses are given (except where emergency vaccination coverage is required).
Perhaps what confuses this issue, is the fact that vaccine potency assessments (PD50 etc..) are done after only one dose - at ~21 days post vaccination. In my opinion, more studies are required to investigate the impact of booster doses - particularly wrt looking at the antibody titres and the clinical outcomes (protected vs not protected).